



## RESEARCH ARTICLE

# REVISED Mutation spectrum analysis of *DMD* gene in Indonesian Duchenne and Becker muscular dystrophy patients [version 3; peer review: 2 approved]

Ery Kus Dwianingsih <sup>1-3</sup>, Kristy Iskandar<sup>1,4,5</sup>, Sunartini Hapsara<sup>4,5</sup>, Chun Ping Liu<sup>6</sup>, Rusdy Ghazali Malueka<sup>1,2,7</sup>, Gunadi<sup>1,2,8</sup>, Masafumi Matsuo<sup>9</sup>, Poh San Lai <sup>6</sup>

<sup>1</sup>Genetics Working Group, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

<sup>2</sup>Dr. Sardjito General Hospital, Yogyakarta, 55281, Indonesia

<sup>3</sup>Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

<sup>4</sup>Academic Hospital, Universitas Gadjah Mada, Yogyakarta, 55291, Indonesia

<sup>5</sup>Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

<sup>6</sup>Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore

<sup>7</sup>Department of Neurology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

<sup>8</sup>Pediatric Surgery Division, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

<sup>9</sup>KNC Department of Nucleic Acid Drug Discovery, Faculty of Rehabilitation, Kobegakuin University, Kobe, 651-2180, Japan

**V3** First published: 07 Feb 2022, 11:148  
<https://doi.org/10.12688/f1000research.73476.1>  
 Second version: 07 Feb 2023, 11:148  
<https://doi.org/10.12688/f1000research.73476.2>  
 Latest published: 17 Nov 2023, 11:148  
<https://doi.org/10.12688/f1000research.73476.3>

## Abstract

### Background

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations in the *DMD* gene. The full mutation spectrum of the *DMD* gene in Indonesian patients is currently unknown. Mutation-specific therapies are currently being developed, such as exon skipping or stop codon read-through therapy. This study was conducted with the aim of identifying the mutation spectrum of the *DMD* gene in Indonesia to guide future development and application of feasible therapeutic strategies.

### Methods

This study is a cross sectional study that enrolled 43 male patients

## Open Peer Review

Approval Status

	1	2
<b>version 3</b>		
(revision)		
17 Nov 2023		
<b>version 2</b>		
(revision)		
07 Feb 2023		
<b>version 1</b>		
07 Feb 2022		

- Teguh Haryo Sasongko** , Perdana University-RCSI, Serdang, Malaysia  
Perdana University-RCSI, Serdang, Malaysia
- Luca Bello** , University of Padova, Padova,

with a clinical suspicion of *DMD* or *BMD*. Multiplex ligation-dependent probe amplification (MLPA) reaction was performed to screen for the common mutations in the *DMD* gene.

### Results

Out of 43 subjects, deletions accounted for 69.77% (n=30) cases, while duplications were found in 11.63% (n=5) cases. One novel duplication spanning exons 2 to 62 was identified. Deletion mutations clustered around the distal (66.67%) and proximal (26.67%) hot spot regions of the *DMD* gene while duplication mutations were observed solely at the proximal region. Two false positive cases of single exon deletion detected through MLPA were attributed to sequence mutations affecting primer ligation sites, confirming the need to validate all single exon deletions when using this screening method. Analysis of available maternal DNA samples showed that the rate of de novo mutations (48.15%) appears higher than expected in this population. Out of 31 patients who were classified as *DMD* based on clinical and genotype characterizations, 60.47% (n=26) of cases were suitable for exon skipping therapy.

### Conclusion

This is the first comprehensive study showing the feasibility of implementing the MLPA method for routine screening of *DMD* patients in Indonesia. This is also the first study showing the potential applicability of exon skipping therapy in the majority of *DMD* cases in the country.

### Keywords

Duchenne muscular dystrophy, Becker muscular dystrophy, *DMD* gene, mutation analysis, Indonesia, MLPA

Italy

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the [Genomics and Genetics gateway](#).

**Corresponding author:** Poh San Lai ([paelaips@nus.edu.sg](mailto:paelaips@nus.edu.sg))

**Author roles:** **Dwianingsih EK:** Conceptualization, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Iskandar K:** Conceptualization, Investigation, Resources; **Hapsara S:** Conceptualization, Funding Acquisition, Methodology, Supervision; **Ping Liu C:** Data Curation, Resources, Software; **Malueka RG:** Formal Analysis, Software, Validation, Visualization, Writing – Review & Editing; **Gunadi :** Funding Acquisition, Software, Validation, Visualization; **Matsuo M:** Conceptualization, Methodology, Supervision; **Lai PS:** Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This study was supported by the NUS-UGM-Tahir Foundation grant. The funding body had no influence on the study design, data analysis, interpretation of data and writing of the manuscript.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2023 Dwianingsih EK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Dwianingsih EK, Iskandar K, Hapsara S *et al.* **Mutation spectrum analysis of DMD gene in Indonesian Duchenne and Becker muscular dystrophy patients [version 3; peer review: 2 approved]** F1000Research 2023, 11:148 <https://doi.org/10.12688/f1000research.73476.3>

**First published:** 07 Feb 2022, 11:148 <https://doi.org/10.12688/f1000research.73476.1>

**REVISED Amendments from Version 2**

After receiving feedback from the reviewers, we have made several changes to the manuscript. These changes include addressing issues related to out-of-frame duplication, deletion, and nonsense mutation. We have also added information to the discussion section regarding a 12-nucleotide deletion in exon 65, pediatric cases, and founder mutations. Furthermore, we have corrected the omission of Figure 5 and amended the spelling of "Gower" to "Gowers". Lastly, we have updated reference 3 to ensure accuracy.

**Any further responses from the reviewers can be found at the end of the article**

**Introduction**

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders arising due to mutations in the *DMD* gene.<sup>1</sup> The *DMD* gene is one of the largest genes in the human genome with a size of more than 2 Mb. This gene spans 79 exons and codes for a 14 kb mRNA that translates a cytoplasmic protein called dystrophin. Due to this large size, mutation detection poses a challenge for routine molecular diagnosis in a clinical setting in many developing countries. Dystrophin protein interacts with other glycoproteins in cell membranes forming the dystrophin-glycoprotein complex (DGC) which stabilizes the membranes of muscle fibers.<sup>2</sup> The absolute absence of dystrophin leads to a clinical manifestation of muscle weakness from early childhood in DMD. Subsequent progressive muscle weakness leads to death before the third decade of life due to respiratory or cardiac failure. The presence of partially functional protein results in BMD, a milder phenotype of the disease.<sup>3</sup>

DMD is the most frequently inherited muscle disease and reported to affect one in every 3,500 male births.<sup>1</sup> Indonesia is one of the largest countries in the world, with a population of 260 million.<sup>4</sup> This suggests that there should be many more DMD cases in Indonesia than the small number of cases that have been reported.<sup>5</sup> The true incidence of the disease and the underlying genetic variants are unknown in this region. Lack of awareness of the clinical features associated with the disease and limited use of molecular testing may lead to many undetected cases, resulting in an iceberg phenomenon of under-diagnosis and under-reporting of DMD cases.

Genetic analysis to detect *DMD* gene mutation is now a gold standard to diagnose DMD/BMD. However, this is not being performed regularly in developing countries like Indonesia. Gene deletions and duplications are reported to be the most common mutations in the *DMD* gene, encompassing more than 60% of cases.<sup>6</sup> Multiplex ligation-dependent probe amplification (MLPA) reaction, a quantitative PCR-based technique, is currently used to routinely amplify all 79 exons of the *DMD* gene to detect deletions and/or duplications in patients.<sup>7</sup> Meanwhile, the identification of point and small mutations for non-deletion or non-duplication cases remains challenging for resource poor labs because of the large number of exons in the *DMD* gene that requires sequence-by-sequence screening. As such, there is currently a lack of knowledge on the true mutation profile in Indonesian DMD/BMD patients. Future applications of mutation-specific molecular therapies, such as exon skipping, CRISPR-Cas9 mediated correction or stop codon read-through therapy, are currently being investigated for patients carrying mutations such as deletions, duplications, and small mutations.<sup>8</sup> Precise mutations analysis is thus necessary to apply the appropriate strategies to patients who are eligible for such treatments.<sup>8</sup> Thus, the objective of this study was to identify the spectrum of common deletion and duplication mutations in the *DMD* gene for clinically diagnosed patients in the Indonesian population using the MLPA technique. The study was carried out with a view to informing future therapeutic applications and developing specific approaches for disease management.

**Methods****Patients**

Forty-three male patients from Dr. Sardjito Teaching Hospital and Universitas Gadjah Mada (UGM) Academic Hospital, Yogyakarta, Indonesia were enrolled in this study, from 2017 to 2018. Clinical manifestations of DMD/BMD were found in the patients and supported by the findings of high serum creatine kinase (CK) levels through medical record data. Clinical diagnosis was made by qualified and experienced pediatric neurologists who are also trained molecular geneticists. Up to now, patients have been followed for their clinical management. Genetic analysis was performed based on approval of parents through signed written informed consent. The study protocol was approved by the Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada (KE/FK/0890/EC/2018) and National University of Singapore Institutional Review Board (N-19-102E).

**Immunohistochemical analysis**

Out of 43 subjects, 23 subjects additionally consented to undergo a muscle biopsy procedure. Muscle biopsy in the form of formalin-fixed paraffin-embedded (FFPE) samples were sliced into 3  $\mu$ m thickness, incubated, deparaffinized, and rehydrated. Antigen retrieval was performed using a Decloaking Chamber NxGen (BioCare Medical, USA) and

immunostained with mouse monoclonal Dys-2 antibody (Novocastra, Leica Biosystem, Newcastle, UK, product code NCL-Dys-2, lot number 6062727) to detect dystrophin expression against carboxyterminal domain with dilution 1:25 in phosphate buffer saline (PBS). Diamino-benzidine (DAB) for visualization of positive cells was applied with a semi-automatic IntelliPATH FLX (BioCare Medical, USA) according to the manufacturer's instructions. Dys-2 expression was observed under a light microscope by an independent and experienced pathologist by analysing the expression of dystrophin in muscle membrane. Negative expression of Dys-2 is considered as indicative of DMD while faint or focal staining suggests BMD, with normal muscle tissue used as a positive control.

### Genomic DNA extraction

Genomic DNA was isolated from 3 mL of EDTA peripheral whole blood samples using Geneaid™ DNA Isolation Kit (Geneaid Biotech Ltd) according to manufacturer's protocol.

### Genetic testing

MLPA analysis was conducted to screen all exons of the *DMD* gene using SALSA MLPA P034 and P035 probe sets (MRC Holland, Netherlands).<sup>7</sup> The procedure was performed according to the manufacturer's protocol. Amplified products were separated using the ABI 3130xl Genetic analyzer and data were analyzed by *Coffalyser* software (MLPA analysis software by MRC-Holland). Patients with single exon deletion were confirmed using conventional PCR. DNA samples from normal healthy individuals were used as reference controls and included in every run. The primer sequences used to amplify the DNA were:

47F 5'-CGTTGTTGCATTGTCTGTTTCAGTTAC-3', 47R 5'-GTCTAACCTTTATCCACTGGAGATTTG-3' (181bp);  
51F 5'-GAAATTGGCTCTTTAGCTTGTGTTTC-3', 51R 5'-GGAGAGTAAAGTGATTGGTGGAAAATC-3' (388bp);  
52F 5'-AATGCAGGATTTGGAACAGAGGCGTCC-3', 52R 5'-TTCGATCCGTAATGATTGTTCTAGCCTC-3' (113bp);  
and 65F 5'-ATTCTCAGAGGAAAAAGGACACTG-3', 65R 5'-GTCTAACCTTTATCCACTGGAGATTTG-3' (369bp).

PCRs were performed in a volume of 25 µL containing 2 µL of genomic DNA, 12.5 µL of 2× Go Taq green Master Mix, 1 µL of each primer, and 8.5 µL of nuclease-free water. The PCR cycling conditions of exon 47 were as follows: initial denaturation at 95 °C for two minutes followed by 35 cycles of denaturation at 95 °C for one minute, annealing at 50 °C for one minute, and extension at 72 °C for one minute. Amplification of other exons used the same PCR condition, however, the annealing time of exons 51 and 52, was 50 °C, meanwhile exon 65 was 55 °C. The amplified exons were then sequenced and analyzed for their mutation's status.<sup>9</sup>

Reading frame analysis was performed using online software *LOVD exonic deletions/duplications reading-frame checker* based on predicted translation of the *DMD* mRNA arising from the identified deletion/insertion (duplication) of the affected exons. Identified mutations were also compared against previously reported mutations using the *UMD-DMD France* mutation database (<http://www.umd.be/>) and the *Leiden Muscular Dystrophy pages* mutation database accessed on June 6<sup>th</sup>, 2021.

## Results

### Demographic and clinical profile

All 43 subjects recruited for this study were male and showed clinical features of DMD/BMD such as difficulty in walking, muscle weakness, positive Gowers sign at age of onset and increased CK levels in their blood samples. CK levels were elevated, ranging from 1,734 to 40,429 IU/L (mean 9,121.7 IU/L, two patients with unavailable data). The age of onset of the disease ranged from one to nine years old (mean 5.1 years old). Nineteen patients (44.18%) were wheelchair bound, with loss of ambulation starting between nine to 13 years old, with mean age at 11 years old (Table 1).

Out of 43 patients, 35 (81.40%) cases of deletion and duplication could be detected using the MLPA method. Deletions accounted for 69.77% (30 cases), while duplications were found in 11.63% (five cases). Two patients who were initially found to have single exon deletion by MLPA turned out to carry small mutations after further investigation. In the remaining eight patients (18.60%), no deletion nor duplication was detected (Table 1). The identified mutations were screened against two well-known DMD databases, namely *UMD-DMD France* and *Leiden Muscular Dystrophy pages* database. Two cases with a novel mutation were identified: dmd19 and dmd21 with duplication spanning exons 2 to 62 (c. (241)\_ (9433)dup) (Table 1).

### Immunohistochemistry results

Out of 23 patients who underwent muscle biopsy, 18 cases (78.26%) showed negative expression of Dys-2 in muscle membrane, suggesting DMD, meanwhile the remaining five cases (21.74%) expressed faint and patchy staining, suggestive of BMD. However, eight discrepant cases were identified. Five faintly staining cases (dmd10, dmd11,

**Table 1.** Demographic, clinical and genetic characteristic of Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) patients.

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Genotyping	Phenotyping
1	dmd1	4906	6	10	11	Waddling gait, tiptoe walk, prone to falls, unable to climb stairs, unable to sit without assistance, Gowers sign (+), gross and fine motor skill delay, pseudohypertrophy	n/a	del 46-48		Out-frame	DMD	DMD
2	dmd4	4135	5	12	21	Waddling gait, tiptoe walk, prone to falls, unable to climb stairs, unable to sit without assistance, Gowers sign (+), gross motor skill delay, low birth weight, pseudohypertrophy, scoliosis	negative staining	no del/no dup		n/a	n/a	DMD
3	dmd5	10499	5	10	12	Waddling gait, tiptoe walk, prone to falls, Gowers sign (+), gross motor skill delay, cardiomegaly, scoliosis, ankle deformity	negative staining	del 53-54		Out-frame	DMD	DMD
4	dmd6	17388	4	not yet	5	Unable to climb stairs and sit without assistance, Gowers sign (+), cardiomegaly, mild scoliosis	n/a	Del 46-50		Out-frame	DMD	DMD
5	dmd8	2020	4	10	13	Difficulty in walking, prone to falls, Gowers sign (+), severe obstructive defect of respiratory tract, scoliosis	negative staining	del 17-43		Out-frame	DMD	DMD

**Table 1.** *Continued*

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Geno-typing	Pheno-typing
6	dmd9	3932	5	10	14	Difficulty in walking, prone to falls, Gowers sign (+), scoliosis, pneumonia, knee contracture, malnutrition	n/a	del 45-52		Out-frame	DMD	DMD
7	dmd10	11152	5	not yet	7	Tiptoe walk, prone to falls, difficulty in standing, Gowers sign (+), mild scoliosis	faint staining	del 51	del 51	Out-frame	DMD	DMD
8	dmd11	16550	4	not yet	8	Prone to falls, difficulty in walking, Gowers sign (+), mild scoliosis, right coxae deformity	faint staining	del 46-51		Out-frame	DMD	DMD
9	dmd14	10846	5	not yet	7	Waddling gait, prone to falls, tip toe walk, Gowers sign (+), gross and fine motor skill delay, speech delay	negative staining	no del/no dup		n/a	n/a	DMD
10	dmd15	3125	8	not yet	9	Prone to falls, difficulty in walking and climbing, Gowers sign (+)	negative staining	del 48-50		Out-frame	DMD	DMD
11	dmd16	8871	4	9	9	Difficulty in walking, Gowers sign (+), pseudohypertrophy, scoliosis	negative staining	del 45-52		Out-frame	DMD	DMD
12	dmd 17	6239	5	not yet	6	Difficulty in walking, prone to falls, Gowers sign (+)	negative staining	del 52	del 52	Out-frame	DMD	DMD
13	dmd18	3255	6	10	13	Lost ambulatory, difficulty in walking, Gowers sign (+), gross and fine motor skill delay, speech delay, right lower leg deformity	n/a	del 65	c.9540-9551 del CTGGCTGCTGAA	In-frame	BMD	DMD

**Table 1.** *Continued*

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Genotyping	Phenotyping
14	dmd19	6924	5	not yet	6	Difficulty in walking, Gowers sign (+), pseudohypertrophy, muscle weakness	negative staining	dup 2-62*		Out-frame	DMD	DMD
15	dmd20	12948	7	not yet	10	Difficulty in walking, prone to falls, waddling gait, Gowers sign (+), gross and fine motor skill delay	negative staining	del 7-43		In-frame	BMD	BMD
16	dmd21	28060	6	not yet	7	Difficulty in walking and climbing, prone to falls, waddling gait, Gowers sign (+), gross and fine motor skill delay, speech delay, muscle weakness, pneumonia	negative staining	dup 2-62*		Out-frame	DMD	DMD
17	dmd22	no data	5	7	14	Difficulty in walking, Gowers sign (+)	n/a	no del/no dup				DMD
18	dmd24	11433	5	Still ambulant	9	Difficulty in walking, Gowers sign (+)	n/a	del 47-50		Out-frame	DMD	DMD
19	dmd25	NA	1	Still ambulant	6	Difficulty in walking and climbing, prone to falls, Gowers sign (+), gross motor skill delay	n/a	del 49-52		Out-frame	DMD	DMD
20	dmd26	40429	6	Still ambulant	6	Difficulty in walking, Gowers sign (+)	n/a	no del/no dup		n/a	n/a	DMD
21	dmd27	8961	6	Still ambulant	6	Difficulty in walking and climbing, tiptoe walking, prone to falls, Gowers sign (+), muscle weakness	negative staining	no del/no dup		n/a	n/a	DMD
22	dmd28	4137	9	Still ambulant	9	Difficulty in walking, tiptoe walking, prone to falls, Gowers sign (+), muscle weakness, scoliosis	negative staining	del 47	c.6808 del T (stop codon)	Out-frame	DMD	BMD



Table 1. Continued

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Genotyping	Phenotyping
23	dmd29	8340	5	9	18	Difficulty in walking, tiptoe walking, prone to falls, Gowers sign (+), difficulty in breathing, muscle atrophy, upper and lower extremity joint contracture, scoliosis, bedridden	n/a	no del/no dup		n/a	n/a	DMD
24	dmd30	8751	4	8	8	Difficulty in walking, prone to falls, Gowers sign (+), gross and fine motor skill delay, inferior flaccid paresis	negative staining	del 51-54		Out-frame	DMD	DMD
25	dmd31	9603	5	10	10	Difficulty in walking, tiptoe walking, Gowers sign (+), gross motor skill delay, speech delay, scoliosis	n/a	del 3-44		In-frame	BMD	DMD
26	dmd33	7482	6	Still ambulant	9	Waddling gait, prone to falls, difficulty in walking, Gowers sign (+), gross motor skill delay, pseudohypertrophy	n/a	no del/no dup		n/a	n/a	DMD
27	dmd34	6746	2	9	10	Walking difficulty, tiptoe walking, Gowers sign (+), muscle weakness, pseudohypertrophy, scoliosis	negative staining	del 49-50		Out-frame	DMD	DMD
28	dmd35	15448	6	Still ambulant	9	Walking difficulty, tiptoe walking, Gowers sign (+), muscle weakness	faint staining	dup 14-17		Out-frame	DMD	DMD

Table 1. Continued

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Genotyping	Phenotyping
29	dmd36	6857	4	Still ambulant	8	Walking difficulty, waddling gait, tip toe walking, prone to falls, Gowers sign (+), pseudohypertrophy, lordosis	negative staining	del 18-47		Out-frame	DMD	DMD
30	dmd37	3337	5	Still ambulant	7	Walking difficulty, waddling gait, tip toe walking, gross motor skill delay, speech delay, Gowers sign (+), pseudohypertrophy, muscle weakness, malnutrition	negative staining	del 56-74		Out-frame	DMD	DMD
31	dmd38	6607	7	7	8	Walking difficulty, tiptoe walking, Gowers sign (+), muscle weakness, pseudohypertrophy, lordosis	negative staining	del 45-49		In-frame	BMD	BMD
32	dmd39	2678	5	10	11	Unable to stand up and walk, muscle weakness	faint staining	del 18-34		Out-frame	DMD	DMD
33	dmd42	1368	5	9	14	Prone to falls, difficulty in walking, ankle contracture, scoliosis	n/a	dup 2-44		Out-frame	DMD	DMD
34	dmd44	12324	5	Still ambulant	9	Difficulty in walking, Gowers sign (+)	n/a	del 48-52		Out-frame	DMD	DMD
35	dmd47	13896	4	Still ambulant	6	Difficulty in walking, Gowers sign (+)	n/a	del 49-50		Out-frame	DMD	DMD
36	dmd48	7800	2	13	14	Difficulty in walking, Gowers sign (+)	n/a	del 3-7		Out-frame	DMD	DMD
37	dmd49	9569	9	Still ambulant	12	Difficulty in walking, Gowers sign (+)	n/a	del 3-7		Out-frame	DMD	DMD

**Table 1.** *Continued*

No	Patient ID	CK level	Age of onset	Age when wheelchair bound	Current age	Clinical features	IHC (dys2)	MLPA	PCR & sequencing validation for single exon deletion	Reading frame prediction	Genotyping	Phenotyping
38	dmd50	7629	4	9	9	Difficulty in walking and climbing the stairs; easy to fall, Gowers sign (+), muscle spasm	n/a	del 5-7		Out-frame	DMD	DMD
39	dmd51	7800	4	10	12	Tiptoe walk, prone to falls, unable to run, Gowers sign (+), gross and fine motor skill delay, muscle spasm, Achilles' contracture	n/a	del 3-17		Out-frame	DMD	DMD
40	dmd53	4865	5	Still ambulant	9	Tiptoe walk, prone to falls, difficulty in climbing stairs, Gowers sign (+), muscle weakness, malnutrition	negative staining	del 51	del 51	Out-frame	DMD	DMD
41	dmd54	1734	6	9	11	Difficulty in walking, Gowers sign (+), scoliosis	faint staining	dup 2-18		Out-frame	DMD	DMD
42	dmd60	13100	5	Still ambulant	10	Difficulty in walking, Gowers sign (+)	n/a	del 49-52		Out-frame	DMD	DMD
43	dmd61	11367	5	Still ambulant	9	Difficulty in walking, prone to falls, Gowers sign (+), gross motor skill delay, muscle weakness	n/a	no del/no dup		n/a	n/a	DMD

CK: serum creatine kinase; IHC: immunohistochemistry; MLPA: multiplex ligation-dependent probe amplification; n/a: not available; del: deletion; dup: duplication.  
 \*Novel mutation.

**Table 2. Discrepancies among genotype, phenotype, and immunohistochemistry (IHC) staining.**


Subject	Molecular genotype	Clinical phenotype	IHC results (protein)
dmd10	Out-frame (del 51)	DMD	±
dmd11	Out-frame (del 46–51)	DMD	±
dmd18	In-frame (del 65)	DMD*	n/a
dmd20	In-frame (del 7–43)	BMD	-
dmd28	Out-frame (del 47)	BMD*	-
dmd31	In-frame (del 3–44)	DMD*	n/a
dmd35	Out-frame (dup 14–17)	DMD	±
dmd38	In-frame (del 45–49)	BMD	-
dmd39	Out-frame (del 18–34)	DMD	±
dmd54	Out-frame (dup 2–18)	DMD	±

DMD: Duchene muscular dystrophy; BMD: Becker muscular dystrophy; n/a: not available; (-): negative staining; (±): patchy staining.  
 \*Genotype-phenotype discrepancy.


dmd35, dmd39 and dmd54) had out-of-frame mutations, two cases (dmd20 and dmd38) with negative immunostaining were found to carry in-frame mutations, and one case (dmd28) with negative immunostaining carried an out-of-frame mutation but clinically had mild symptoms (Table 2).

**Deletion pattern in the DMD gene**

Initially, 30 deletions (69.77%) cases were discovered using MLPA, consisting of 25 cases with multi-exon deletions and five cases with single exon deletions of exon 47, exon 51, exon 52 and exon 65. Single exon deletion cases were further analysed by PCR. Three cases were confirmed to have single exon deletion of exons 51 or 52. After sequencing, a case with deletion in exon 47 turned out to carry a nonsense mutation (c.6808 del T, p.Leu2271StopCodon) which was discordant with the clinical symptoms of BMD seen in the patient (dmd28). Meanwhile, one case with a deletion in exon 65 (dmd18) turned out to carry a small in-frame deletion of 12 nucleotides (c. 9540–9551 del CTGGCTGCTGAA, p. Asn3180–3184Asn). This was clinically discordant with the DMD condition observed in the patient (Table 1). The largest exon deletion in this study spanned exons 3 to 44 (one case). Other large deletions encompassed exons 17–43, exons 7–43, exons 18–47, exons 3–17, exons 48–52, and exons 56–74. The most common type of deletions were deletions of exons 45 to 52, exons 49 to 52, exons 49 to 50, exons 3 to 7 and single deletion of exon 51 (two cases each, respectively) (Table 1). Deletion mostly occurred in the distal hot spot region (exons 45–55) with 20 cases (66.67%) carrying deletions in this region. In eight cases (26.67%) deletions occurred in the proximal hot spot (exons 2–20) region (Figures 1 and 2).



**Figure 1. Frequencies of deletion of DMD gene exons in Indonesian Duchenne muscular dystrophy/Becker muscular dystrophy patients (n=28).**



**Figure 2. Distribution pattern of exon deletions in Indonesian Duchenne muscular dystrophy/Becker muscular dystrophy patients (n=28).** Most exon deletions occurred in rod domain of *DMD* gene. Out-frame deletions indicated in orange boxes, while in-frame deletions indicated in blue boxes.


### Duplications pattern in the *DMD* gene

Out of the 43 DMD cases, duplications occurred in five patients (11.63%): four cases had duplications initiating from exon 2, and one case starting from exon 14. The highest frequency of duplications occurred in exons 14 to 17, found in all five patients. The largest duplication spanned from exons 2 to 62 affecting 40% of these cases (two patients), and the shortest duplication covered exons 14 to 17 in 20% (one patient) (Figures 3 and 4). All duplications (100%) involved the proximal hot spot region.


### Association with reading frames

Out of the 30 patients with deletions, only four cases were in-frame, and the remaining 26 cases were out-of-frame (Table 1). One discrepancy was dmd31, with a mutation predicted as in-frame (del 3–44); however, the phenotype was DMD. Meanwhile two cases with single exon deletions detected initially by MLPA turned out to carry a nonsense mutation (case dmd28) and a 12-nucleotide deletion (case dmd18) by sequencing. These mutations were out-frame and in-frame respectively. Both cases were discordant with the reading frame predictions as dmd28 showed a milder phenotype whereas dmd18 showed a severe clinical condition (Table 2). In five patients carrying duplications of the *DMD* gene, all were out-of-frame with DMD phenotype.

Based on immunohistochemical staining results, three cases (dmd20, dmd28 and dmd38) showed negative staining of dystrophin, however the patients manifested milder phenotype of BMD. Meanwhile five cases (dmd10, dmd11, dmd35, dmd39, and dmd54) showed faint staining of dystrophin (Table 2), even though the genotype–phenotype correlations were consistent with DMD. Among the novel mutations found in this study, two of them (duplication of exon 2 to 62 and deletion of exon 56 to 74) were out-of-frame, while the deletion of exon 7 to 43 was an in-frame mutation (Table 2). Overall, out of 35 patients with deletion and duplication, 32 patients (91.43%) were in accordance with the reading frame rule, meanwhile three (8.57%) patients were discordant (Table 2).



**Figure 3.** Frequencies of duplication of *DMD* gene exons in Indonesian Duchenne muscular dystrophy/Becker muscular dystrophy patients (n=5).



**Figure 4.** Distribution pattern of exon duplications in Indonesian Duchenne muscular dystrophy/Becker muscular dystrophy patients (n=5). All exon duplications occurred in the rod domain of the *DMD* gene and revealed as out-frame mutations (indicated in orange boxes). In-frame duplication was not detected.

**Other clinical parameters**

Out of the 43 patients, 18 patients (41.86%) manifested skeletal deformities, including scoliosis in 14 cases (32.56%), lordosis in two cases (4.65%), ankle deformity in two cases (4.65%), coxae deformity in one case (2.32%), knee deformity in one case (2.32%), and lower leg deformity in one case (2.32%). Some patients had more than one skeletal deformity, such as scoliosis coexisting with ankle deformity. One patient (2.32%) was born with low birth weight, three patients (6.98%) suffered from malnutrition and two patients (2.32%) were reported to have cardiomegaly. Six patients (13.85%) showed early signs of respiratory tract disturbance, such as difficulty in breathing and pneumonia. Some patients reported history of milestone developmental problems, including gross motor skill delays in 14 patients (32.56%), fine motor skill delays in seven patients (16.28%) and speech delays in five patients (11.62%) (Table 1).

### Carrier status

Carrier status analysis was performed on mothers and female siblings of patients found to carry deletion or duplication mutations through MLPA analysis. Family members of the patients without deletion or duplication did not undergo this analysis. Twenty-seven available samples from mothers showed that carrier status was confirmed in 14 cases (51.85%). Five available samples from female siblings of probands showed one case (20%) carrying the mutated *DMD* gene, meanwhile, the remaining four cases (80%) were negative for the identified mutation in their affected brother.

### Molecular therapy applicability

Out of 31 patients whose genotype data was consistent with severe DMD, 46.51% cases are amenable for the application of exon skipping therapy. Therapeutic approaches to skip exons 51, 53, 45, 50, 17, 2, 44, and 8 can be applied in 20 patients (46.51%). The mutation spectrum and molecular therapy applicability for the identified mutations are presented in [Tables 3 and 4](#).

**Table 3. Cases amenable for molecular therapies.**

Molecular therapies	Type of mutation	Applicable cases	
		n	(%)
<b>Skipping of</b>			
Exon 51	del48–50, del52, del47–50, del49–50	5	11.63
Exon 53	del45–52, del48–52, del49–52	5	11.63
Exon 45	del46–48, del46–51	2	4.65
Exon 50	del 51	2	4.65
Exon 17	del18–47, del18–34	2	4.65
Exon 2	del3–7	2	4.65
Exon 44	del17–43	1	2.33
Exon 8	del5–7	1	2.33

**Table 4. Comparisons of applicability of current molecular therapy reported across different countries (selected examples).**

No	Country	Patient number	Del (%)	Dup (%)	Other mutations (%)	No del/No dup (%)	Applicability for current molecular therapies
1	USA (Flanigan <i>et al.</i> , 2009)	111	42.9	11	46	(-)	Single exon skipping 59.6%
2	Japan (Takeshima <i>et al.</i> , 2011)	442	61	9	29	(-)	single exon skipping 47% (exons 51, 50, 45, 44, 8, 43, 52, 55)
3	India (Polavarapu <i>et al.</i> , 2019)	606	81.2	5.4	11.5	1.3	single exon skipping 38.6% (exon 45, 51, 53)
4	Singapore (Tomar <i>et al.</i> , 2019)	145	65.5	9.7	21.4	(-)	Single exon skipping 51.6%, multiple exon skipping 32.3%
5	Kuwait (Mohammed <i>et al.</i> , 2018)	68	66	5	10	13	Single exon skipping of 16% (exon 51)
6	Eastern European: Poland, Hungary, Lithuania, Romania, Serbia, Croatia, Bosnia, Bulgaria, Ukraine, and Russia (Selvatici <i>et al.</i> , 2021)	328	29	11	59	(-)	Single exon skipping 59% (exons 53, 51, 45, 44), 27% for read through

**Table 4.** *Continued*

No	Country	Patient number	Del (%)	Dup (%)	Other mutations (%)	No del/No dup (%)	Applicability for current molecular therapies
7	Malaysia (Rani <i>et al.</i> , 2011)	35	77	6	17	(-)	Single exon skipping 24% (exon 45)
8	Indonesia (this study)	43	65.11	11.63	2.3	23.25	Single exon skipping 60% (exons 51, 53, 45, 50, 17, 2, 44, 8, 55, 63, 18, 19), 2.3% read through

del: deletion; dup: duplication; (-): unknown/data not provided.

### Discussion

In DMD/BMD, the increased permeability of the sarcolemma allows CK from muscle fibers to be released to blood stream, indicating a muscle damage process. The highest levels of CK are commonly observed between two to five years of age and decreases along with disease progression and older age.<sup>10</sup> This pattern is similar to what is observed in the DMD/BMD patients in our study, which also showed high CK levels with mean age of onset at five years of age.

The analysis of fresh frozen muscle specimens is usually a standard procedure for muscle biopsy, however this service is not currently available in Indonesia. Instead, FFPE samples from muscle specimens were used to detect dystrophin expression in sarcolemma membrane. Similar use of such FPPE samples have been previously reported in Thailand, Japan and UK, showing this as a reliable and reproducible technique.<sup>11</sup> Our immunohistochemistry (IHC) analysis showed weak staining of dystrophin protein in five DMD patients. Trace-level dystrophin expression in patients with out-of-frame DMD mutations has been previously reported in approximately 20% of DMD patients.<sup>12,13</sup> The mechanism for this low level of dystrophin has not been fully understood. Possible mechanisms include re-initiation of translation downstream of frameshift mutation and alternative splicing of exon adjacent to deletion boundaries resulting in restoration of open reading frame.<sup>14</sup> Indeed, a study by our group previously showed that the formation of splicing silencer by *DMD* exon 45 deletion junction could explain exon 44 skipping, thereby restoring open reading frame.<sup>15</sup> Three other cases with negative dystrophin staining were inconsistent with the BMD genotypes and phenotypes observed. The negative result of dystrophin staining could be due to subjectivity in evaluating the IHC result or insufficient pre-analytical treatment. Moreover, the dystrophin marker used in this study was Dys-2 located in C-terminal, which may not fully capture expression in the rod domain.<sup>16</sup> Due to these limitations and the invasive nature of the muscle biopsy procedure, molecular methods of gene analysis from blood draws offer a better option for diagnosis.

The use of the MLPA technique has improved the detection of both single and large intragenic rearrangements because it allows the simultaneous analysis of all 79 exons in the *DMD* gene, the largest gene in the human genome. Prior to the MLPA technique, approaches such as multiplex PCR using primers that cover sets of commonly deleted exons would yield deletion rates ranging from 40% to 51.2% of DMD/BMD cases as reported in some Asian populations.<sup>17</sup> *DMD* gene analysis in the Indonesian population has been conducted previously using IHC<sup>18</sup> and multiplex PCR<sup>19</sup> methods. However, precise mutations cannot be identified using the IHC method while multiplex PCR is unable to cover all exons in the *DMD* gene. Our study using MLPA screening showed that deletions were detected in 69.77% cases while duplications were found in 11.63%, providing a molecular diagnosis in 81.4% of total examined cases. This result is comparable to previous MLPA studies of DMD/BMD cases in Asian populations conducted in China 66–95%,<sup>20</sup> India 68%,<sup>21</sup> Vietnam (54%),<sup>22</sup> Malaysia (77%)<sup>23</sup> Japan (70%)<sup>2</sup> and Singapore (75%).<sup>8</sup> MLPA is suitable to be performed in developing countries as a screening method since it is simple and fast and allows the diagnosis of DMD in about 85% of cases with the occurrence of 60–70% deletions and 10–15% duplications in the *DMD* gene found in all DMD patients.<sup>1,21,24–26</sup> This detection will contribute to possible application of exon skipping therapy in 60.47% of DMD cases in our patients, similar to some other studies summarized in Table 4. However, in Kuwait and Malaysia, its applicability is reported to be much lower.<sup>1,8,27–30</sup> Therapy using eteplirsen (skipping of exon 51) and golodirsen (skipping of exon 53), antisense oligonucleotide drugs approved by the FDA, can be applied in 23.25% of patients while codon read through therapy using compounds such as ataluren, can be applied in one patient.

A critical issue in interpretation of MLPA results is the detection of deletions involving a single *DMD* exon. In this study, two single exon deletions detected through MLPA turned out to be small point mutations that involve sequences where the probes should ligate. The altered exon sequences inhibited the proper hybridization of the specific probe, thus leading



to the observed deletion of the respective exon during MLPA analysis. Such sequence variations may involve pathogenic small or point mutations, or even a polymorphism that does not disrupt gene function. Therefore, single exon deletions detected by MLPA should always be confirmed with PCR and sequencing as evidenced by our observations in this study.<sup>31</sup> Two cases (dmd18 and dmd31) in this study were in-frame mutations, but phenotypically DMD. One possible explanation for the discrepant predicted phenotype in dmd18 is that deletion of exon 65 may disrupt binding to  $\beta$ -dystroglycan resulting in a more severe phenotype. However, this requires further investigation. Meanwhile, one case (dmd28) was out-frame in genotype, but phenotypically BMD. Further investigation using mRNA transcripts is needed to reveal the splicing pattern of these cases in order to understand how the discrepancies occurred. Unfortunately, it was not possible to collect additional samples from the patients for further investigations in the current study. Concordance to the reading frame rule in our study was 91.43% (32/35), which is similar to other studies in Asia, including Japan (93%),<sup>1</sup> Singapore (96%),<sup>8</sup> Vietnam (94%), Malaysia (93%)<sup>22</sup> and China (88%).<sup>20</sup>

In contributing towards the spectrum of mutations in the *DMD* gene, one novel mutation was observed in two patients, dmd19 and dmd21, involving a duplication of exons 2 to 62 (c. (-182\_59) (9187\_9246) dup). Duplication frequency is reported to be highest at the 5' end of the gene with exon 2 duplication as the most common single duplication.<sup>1,32</sup> This novel mutation in both patients has been deposited into the Leiden Open Variation Database (LOVD) (ID numbers 00383167 and 00383168).

Previous studies on the mutation spectrum of the *DMD* gene in Japan showed that deletions were found to cluster in a proximal hotspot (exon 2–20) and distal hotspot (exon 45–55), at a frequency of 26% and 65% of all identified deletions, respectively.<sup>1</sup> This study showed similar results as deletions occurred more frequently in the distal hot spot region (66.67%), and only 26.67% were in the proximal hot spot region. Duplication mutations appear to be distributed across the *DMD* gene; however, the proximal hot spot was more frequently duplicated than the distal hotspot,<sup>1</sup> which concurs with our result showing that all duplications (100%) involved the proximal hot spot region.

In this study, the MLPA method was not able to identify deletion nor duplication in eight patients. Small sequence mutations may occur in these cases leading to a negative result in the MLPA since the clinical features were consistent for DMD. Further sequencing analysis using mRNA to detect both point mutation and splicing patterns is needed to reveal the disease-causing mutation. MLPA should be combined with direct Sanger sequencing or whole exome sequencing to obtain higher sensitivity and specificity in the detection of small or point mutations in the *DMD* gene.<sup>33</sup> Additionally, it should be noted that MLPA analysis can generate false positive results by showing an exon deletion when a polymorphism occurs at a primer ligation site.<sup>34</sup> Hence, it is always useful to conduct a confirmatory test using another method.

Previously, DMD patients commonly lost their ambulation prior to 12 years of age and could only survive until their late teens.<sup>35</sup> However, current treatment such as long-term use of corticosteroids has been reported to prolong ambulation by two to five years or even longer, thereby reducing the need of spinal stabilization surgery, improving cardiopulmonary function, delaying the need for noninvasive nasal ventilation, and increasing survival and the quality of life of patients with DMD.<sup>36</sup> Surgical and ventilator support were also reported to increase survival up to the third decade.<sup>37</sup> In our study, the mean age of losing ambulatory ability was still below 12 years old and this may be caused by the difficulty of the patients obtaining early and proper clinical management due to challenges in establishing precise diagnosis. This is due to difficulty in getting access to molecular testing. Muscle biopsy can be performed to help with diagnosis using immunohistochemistry analysis,<sup>18</sup> however, not all medical centers have this facility and not all parents agree to this invasive procedure. Due to such limitations in Indonesia, the disease has not been well characterized. Hence, this current study provides evidence of usefulness of deletion and duplication screening for diagnosis in most patients.

Initially, both DMD and BMD patients show skeletal muscle weakness, marked with positive Gowers sign. The natural course of DMD shows that muscular dystrophy will occur progressively followed by deterioration of cardiac and respiratory muscles, leading to early death due to respiratory or heart failure.<sup>35</sup> Mutations involving exons 12, 14 to 17, 31 to 42, 45, and 48 to 49 have been reported to enhance cardiac involvement.<sup>38</sup> In our study, two patients showed cardiomegaly and only one of them fit with this theory, as this patient had exons 46–50 deletion. Cardiac and respiratory problems were found only in two (2.32%) and six (13.85%) patients, respectively. The small number of patients with cardiac and respiratory problems in this study is perhaps due to the relatively short period of observation. Similar limitations were also encountered in collection of other clinical parameters observed in this study such as musculoskeletal involvement, malnutrition, etc.

Scoliosis is a frequent complication (68–90%) in DMD, meanwhile bone fractures occur in 20–25% of cases and the risk increases along with age and loss of ambulation.<sup>39</sup> In our study, cases of skeletal deformity, including scoliosis, were only

found in 41.86% of patients, less than previous studies. Some patients were also reported to suffer from malnutrition (6.98%). The weight loss in DMD patients is suspected to be associated with progressive muscle weakness leading to dysphagia and mastication dysfunction.<sup>40</sup> Growth delays in individuals with DMD can be observed as short stature<sup>41</sup> or motoric and language delays.<sup>42</sup> Even though short stature was not observed in all subjects, some patients (34.88%) were found to develop motoric and language delays. Even though dystrophin expression in the brain is only one-tenth of that observed in muscle, varying degrees of non-progressing cognitive impairment might be exhibited in some patients.<sup>43</sup> However, no mental retardation was observed in this study.

Theoretically, approximately two-thirds of DMD patients inherit their mutations from carrier mothers, meanwhile the remaining one-third are predicted to develop the disease due to spontaneous mutations.<sup>44</sup> Our results showed that inherited cases were confirmed in 14 cases (51.85%) out of 27 available samples while 13 cases were due to *de novo* mutations (48.15%). These results suggest that the rate of *de novo* mutation in our population is higher than the estimated one-third of all DMD cases. However, there has been one previous study of 150 cases showing a high rate (71%) of *de novo* mutations as compared to the inherited cases which affected only 49 cases (29%).<sup>45</sup> *De novo* mutations are defined by their presence in one or more progenies and the absence in the mother. The presence of multiple affected offspring from apparently non-carrier parents is caused by germline mosaicism as *DMD* mutation evolves *de novo* in the affected patient and the risk of recurrence from germinal mosaicism is estimated to be approximately 4.3%.<sup>46</sup>

MLPA has been used to detect carrier status in probands with known deletion or duplication mutations since it is an easy and quick technique.<sup>47</sup> Detection of carrier status serves to provide essential information for family counselling regarding future pregnancies, improving quality of life and reducing financial burden for at-risk families.<sup>48</sup> This study also shows that MLPA analysis can pave the way for future therapeutics in DMD patients by identifying amenable genotypes that can be targeted.

Mutation detection in DMD is essential for patient management especially since advanced therapy such as exon skipping, CRISPR-Cas9 mediated correction or stop codon read-through therapy are mutation specific approaches. Furthermore, molecular diagnosis is also important for genetic counselling to plan future pregnancy. In our study, MLPA was found to be an easy and quick technique to identify deletion and/or duplication mutation and detect copy number of DMD carriers. This study also showed that the majority (81.40%) of *DMD* gene mutations in Indonesian DMD patients were deletions and duplications. Of these, 60.46% would be amenable to exon skipping therapy. It is important to keep in mind that the data collected in this study was from a single pediatric center. As a result, our study might have excluded milder cases of BMD that only become noticeable in adulthood due to later onset of disease. Further research is necessary to investigate this possibility. Additionally, screening of future patients from more centers in the country can be carried out to add to the existing data in this study. Nonetheless, it should be noted that even when sufficiently large populations of patients are analyzed, the overall genetic composition of dystrophinopathies often yield very similar trends across world populations, as there are no or very few “founder” mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations.

This is the first study showing the feasibility of implementing the MLPA method in detecting *DMD* gene mutation and revealing the spectrum of common mutations in Indonesia. This is also the first study showing the potential application of exon skipping therapy in the majority of DMD cases in the country. The clinical and molecular characterization of patients in this study provide a better insight of DMD and BMD profiles in the Indonesian population and will shape health policies in patient management.

## Data availability

### Underlying data

Figshare: Underlying data for ‘Mutation spectrum analysis of *DMD* gene in Indonesian Duchenne and Becker muscular dystrophy patients’, <https://www.doi.org/10.6084/m9.figshare.15172167.V2>.<sup>9</sup>

This project contains the following underlying data:

- Demographic, clinical and genetic characteristic of Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) patients
- Electrophoresis result of single exon deletion of exon 47, exon 51, and exon 52.
- Electrophoresis result of single exon deletion of exon 47 and exon 65.

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

### Accession numbers\*

Leiden Open Variation Database (LOVD): DMD variant (del 46–48). Accession number DMD\_014648, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014648%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014648%22)

Leiden Open Variation Database (LOVD): DMD variant (del 53–54). Accession number DMD\_105354, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_105354%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_105354%22)

Leiden Open Variation Database (LOVD): DMD variant (del 46–50). Accession number DMD\_014650, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014650%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014650%22)

Leiden Open Variation Database (LOVD): DMD variant (del 17–43). Accession number DMD\_011743, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_011743%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_011743%22)

Leiden Open Variation Database (LOVD): DMD variant (del 45–52). Accession number DMD\_014552, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014552%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014552%22)

Leiden Open Variation Database (LOVD): DMD variant (del 51). Accession number DMD\_015151, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_015151%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_015151%22)

Leiden Open Variation Database (LOVD): DMD variant (del 46–51). Accession number DMD\_014651, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014651%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014651%22)

Leiden Open Variation Database (LOVD): DMD variant (del 48–50). Accession number DMD\_014850, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014850%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014850%22)

Leiden Open Variation Database (LOVD): DMD variant (del 52). Accession number DMD\_015252, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_015252%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_015252%22)

Leiden Open Variation Database (LOVD): DMD variant (del 65). Accession number DMD\_016565, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_016565%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_016565%22)

Leiden Open Variation Database (LOVD): DMD variant (dup 2–62). Accession number DMD\_020262, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_020262%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_020262%22)

Leiden Open Variation Database (LOVD): DMD variant (del 7–43). Accession number DMD\_010743, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_010743%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_010743%22)

Leiden Open Variation Database (LOVD): DMD variant (del 47–50). Accession number DMD\_014750, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014750%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014750%22)

Leiden Open Variation Database (LOVD): DMD variant (del 49–52). Accession number DMD\_014952, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014952%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014952%22)

Leiden Open Variation Database (LOVD): DMD variant (del 47). Accession number DMD\_014747, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014747%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014747%22)

Leiden Open Variation Database (LOVD): DMD variant (del 51–54). Accession number DMD\_015154, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_015154%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_015154%22)

Leiden Open Variation Database (LOVD): DMD variant (del 3–44). Accession number DMD\_010344, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_010344%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_010344%22)

---

\*Representative Accession numbers are shown as some variants have been associated with numerous IDs.

Leiden Open Variation Database (LOVD): DMD variant (del 49–50). Accession number DMD\_014950, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014950%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014950%22)

Leiden Open Variation Database (LOVD): DMD variant (dup 14–17). Accession number DMD\_021417, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_021417%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_021417%22)

Leiden Open Variation Database (LOVD): DMD variant (del 18–47). Accession number DMD\_011847, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_011847%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_011847%22)

Leiden Open Variation Database (LOVD): DMD variant (del 56–74). Accession number DMD\_015674, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_015674%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_015674%22)

Leiden Open Variation Database (LOVD): DMD variant (del 45–49). Accession number DMD\_014549, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014549%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014549%22)

Leiden Open Variation Database (LOVD): DMD variant (del 18–34). Accession number DMD\_011834, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_011834%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_011834%22)

Leiden Open Variation Database (LOVD): DMD variant (dup 2–44). Accession number DMD\_020244, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_020244%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_020244%22)

Leiden Open Variation Database (LOVD): DMD variant (del 48–52). Accession number DMD\_014852, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_014852%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_014852%22)

Leiden Open Variation Database (LOVD): DMD variant (del 3–7). Accession number DMD\_010307, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_010307%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_010307%22)

Leiden Open Variation Database (LOVD): DMD variant (del 5–7). Accession number DMD\_010507, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_010507%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_010507%22)

Leiden Open Variation Database (LOVD): DMD variant (del 3–17). Accession number DMD\_010317, [https://databases.lovd.nl/shared/view/DMD?search\\_VariantOnGenome%2FDBID=%3D%22DMD\\_010317%22](https://databases.lovd.nl/shared/view/DMD?search_VariantOnGenome%2FDBID=%3D%22DMD_010317%22)

Leiden Open Variation Database (LOVD): DMD variant (dup 2–18). Accession number DMD\_020218, <http://www.umd.be/DMD/4DACTION/WV/368>

## Consent

Written informed consent for publication of the patients' details was obtained from the parents of the patients.

## Acknowledgements

We would like to thank Klinik Bahasa of Faculty of Medicine, Public Health and Nursing, UGM for assistance in language editing of this manuscript. We also thank Grace Tan from Department of Pediatrics, NUS for assistance with the sequence nomenclatures of the variants. This study was funded by the National University of Singapore (NUS) - Universitas Gadjah Mada (UGM) Collaboration Seed Fund which was supported by the Tahir Foundation.

## References

1. Takeshima Y, Yagi M, Okizuka Y, *et al.*: **Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center.** *J. Hum. Genet.* 2010; **55**(6): 379–388. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Ervasti JM, Campbell KP: **Membrane organization of the dystrophin-glycoprotein complex.** *Cell.* 1991; **66**(6): 1121–1131. [Publisher Full Text](#)
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, *et al.*: **An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.** *Genomics.* 1988; **2**(1): 90–95. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Tam CC, O'Driscoll M, Taurel AF, *et al.*: **Geographic variation in dengue seroprevalence and force of infection in the urban paediatric population of Indonesia.** *PLoS Negl. Trop. Dis.* 2018; **12**(11): e0006932. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Wedhanto S, Siregar UP: **Duchenne muscular dystrophy.** *Majalah Kedokteran Indonesia.* 2007; **57**(9): 312.

6. Okubo M, Goto K, Komaki H, *et al.*: **Comprehensive analysis for genetic diagnosis of dystrophinopathies in Japan.** *Orphanet J. Rare Dis.* 2017; **12**(1): 149.  
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Schouten JP, McElgunn CJ, Waaijer R, *et al.*: **Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.** *Nucleic Acids Res.* 2002; **30**(12): 57e–557e.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Tomar S, Moorthy V, Sethi R, *et al.*: **Mutational spectrum of dystrophinopathies in Singapore: Insights for genetic diagnosis and precision therapy.** *Am. J. Med. Genet. C Semin. Med. Genet.* 2019; **181**(2): 230–244.  
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Dwianingsih E, Iskandar K, Hapsara S, *et al.*: **Mutation Spectrum Analysis of DMD gene using MLPA method in Indonesian Duchenne and Becker muscular dystrophy patients.** figshare. Dataset. 2021.  
[Publisher Full Text](#)
10. Sun SC, Peng YS, He JB: **Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy.** *Zhongguo Dang Dai Er Ke Za Zhi.* 2008; **10**(1): 35–37.  
[PubMed Abstract](#)
11. Sheriffs IN, Rampling D, Smith VV: **Paraffin wax embedded muscle is suitable for the diagnosis of muscular dystrophy.** *J. Clin. Pathol.* 2001; **54**(7): 517–520.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Arechavala-Gomez V, Kinali M, Feng L, *et al.*: **Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.** *Neuromuscul. Disord.* 2010; **20**(5): 295–301.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Thanh LT, Nguyen TM, Helliwell TR, *et al.*: **Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.** *Am. J. Hum. Genet.* 1995; **56**(3): 725–731.  
[PubMed Abstract](#)
14. Bello L, Pegoraro E: **The “Usual Suspects”: Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular Dystrophy.** *J. Clin. Med.* 2019; **8**(5).  
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Dwianingsih EK, Malueka RG, Nishida A, *et al.*: **A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy.** *J. Hum. Genet.* 2014; **59**(8): 423–429.  
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Hoshino S, Ohkoshi N, Watanabe M, *et al.*: **Immunohistochemical staining of dystrophin on formalin-fixed paraffin-embedded sections in Duchenne/Becker muscular dystrophy and manifesting carriers of Duchenne muscular dystrophy.** *Neuromuscul. Disord.* 2000; **10**(6): 425–429.  
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Lai PS, Takeshima Y, Adachi K, *et al.*: **Comparative study on deletions of the dystrophin gene in three Asian populations.** *J. Hum. Genet.* 2002; **47**(10): 0552–0555.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Dwianingsih EK, Insani MFP, Pratiwi L, *et al.*: **Clinicopathologic and molecular profiles of Duchenne and Becker muscular dystrophy.** *Paediatr. Indones.* 2019; **59**(5): 257–264.  
[Publisher Full Text](#)
19. Iskandar K, Dwianingsih EK, Pratiwi L, *et al.*: **The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: the era of personalized medicine.** *BMC. Res. Notes.* 2019; **12**(1): 704.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Guo R, Zhu G, Zhu H, *et al.*: **DMD mutation spectrum analysis in 613 Chinese patients with dystrophinopathy.** *J. Hum. Genet.* 2015; **60**(8): 435–442.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Murugan S, Chandramohan A, Lakshmi BR: **Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis.** *Indian J. Med. Res.* 2010; **132**: 303–311.  
[PubMed Abstract](#)
22. Tran VK, Ta VT, Vu DC, *et al.*: **Exon deletion patterns of the dystrophin gene in 82 Vietnamese Duchenne/Becker muscular dystrophy patients.** *J. Neurogenet.* 2013; **27**(4): 170–175.  
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Rani AQ, Sasongko TH, Sulong S, *et al.*: **Mutation spectrum of dystrophin gene in Malaysian patients with Duchenne/Becker muscular dystrophy.** *J. Neurogenet.* 2013; **27**(1–2): 11–15.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, *et al.*: **DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations.** *PLoS One.* 2015; **10**(8): e0135189.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Zimowski JG, Massalska D, Holding M, *et al.*: **MLPA based detection of mutations in the dystrophin gene of 180 Polish families with Duchenne/Becker muscular dystrophy.** *Neurol. Neurochir. Pol.* 2014; **48**(6): 416–422.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Ji X, Zhang J, Xu Y, *et al.*: **MLPA application in clinical diagnosis of DMD/BMD in Shanghai.** *J. Clin. Lab. Anal.* 2015; **29**(5): 405–411.  
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Polavarapu K, Preethish-Kumar V, Sekar D, *et al.*: **Mutation pattern in 606 Duchenne muscular dystrophy children with a comparison between familial and non-familial forms: a study in an Indian large single-center cohort.** *J. Neurol.* 2019; **266**(9): 2177–2185.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Flanigan KM, Dunn DM, von Niederhausern A, *et al.*: **Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.** *Hum. Mutat.* 2009; **30**(12): 1657–1666.  
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Mohammed F, Elshafey A, Al-Balool H, *et al.*: **Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.** *PLoS One.* 2018; **13**(5): e0197205.  
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Selvatici R, Rossi R, Fortunato F, *et al.*: **Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries.** *Neurol Genet.* 2021; **7**(1): e536.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Janssen B, Hartmann C, Scholz V, *et al.*: **MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls.** *Neurogenetics.* 2005; **6**(1): 29–35.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, *et al.*: **Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.** *Muscle Nerve.* 2006; **34**(2): 135–144.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Falzarano MS, Scotton C, Passarelli C, *et al.*: **Duchenne muscular dystrophy: from diagnosis to therapy.** *Molecules.* 2015; **20**(10): 18168–18184.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Niba ETE, Tran VK, Tuan-Phamb LA, *et al.*: **Validation of ambiguous MLPA results by targeted next-generation sequencing discloses a nonsense mutation in the DMD gene.** *Clin. Chim. Acta.* 2014; **436**: 155–159.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Andrews JG, Wahl RA: **Duchenne and Becker muscular dystrophy in adolescents: current perspectives.** *Adolesc. Health Med. Ther.* 2018; Volume 9: 53–63.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Moxley RT 3rd, Pandya S, Ciafaloni E, *et al.*: **Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.** *J. Child Neurol.* 2010; **25**(9): 1116–1129.  
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Passamano L, Taglia A, Palladino A, *et al.*: **Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients.** *Acta Myol.* 2012; **31**(2): 121–125.  
[PubMed Abstract](#)
38. Yamamoto T, Awano H, Zhang Z, *et al.*: **Cardiac Dysfunction in Duchenne Muscular Dystrophy Is Less Frequent in Patients With Mutations in the Dystrophin Dp116 Coding Region Than in Other Regions.** *Circ. Genom. Precis. Med.* 2018; **11**(1): e001782.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Muntoni F, Bushby K, Manzur AY: **Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London.** *UK. Neuromuscul. Disord.* 2006; **16**(3): 210–219.  
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Toussaint M, Davidson Z, Bouvoie V, *et al.*: **Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management.** *Disabil. Rehabil.* 2016; **38**(20): 2052–2062.  
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Matsumoto M, Awano H, Lee T, *et al.*: **Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup.** *Neuromuscul. Disord.* 2017; **27**(11): 1023–1028.  
[PubMed Abstract](#) | [Publisher Full Text](#)

42. Mirski KT, Crawford TO: **Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis.** *J. Pediatr.* 2014; **165**(5): 1008–1010.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Rae MG, O'Malley D: **Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules.** *J. Neurophysiol.* 2016; **116**(3): 1304–1315.  
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Lee T, Takeshima Y, Kusunoki N, *et al.*: **Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients.** *J. Hum. Genet.* 2014; **59**(1): 46–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Sakthivel Murugan SM, Arthi C, Thilothammal N, *et al.*: **Carrier detection in Duchenne muscular dystrophy using molecular methods.** *Indian J. Med. Res.* 2013; **137**(6): 1102–1110.
46. Helderman-van den Enden AT, de Jong R, den Dunnen JT, *et al.*: **Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy.** *Clin. Genet.* 2009; **75**(5): 465–472.  
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Verma PK, Dalal A, Mittal B, *et al.*: **Utility of MLPA in mutation analysis and carrier detection for Duchenne muscular dystrophy.** *Indian J. Hum. Genet.* 2012; **18**(1): 91–94.  
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Bogue L, Peay H, Martin A, *et al.*: **Knowledge of carrier status and barriers to testing among mothers of sons with Duchenne or Becker muscular dystrophy.** *Neuromuscul. Disord.* 2016; **26**(12): 860–864.  
[PubMed Abstract](#) | [Publisher Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 3

Reviewer Report 22 November 2023

<https://doi.org/10.5256/f1000research.158228.r223671>

© 2023 Bello L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Luca Bello** 

University of Padova, Padova, Italy

The authors have responded satisfactorily to my comments.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Muscular dystrophy

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 2

Reviewer Report 06 September 2023

<https://doi.org/10.5256/f1000research.143201.r184879>

© 2023 Bello L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Luca Bello** 

<sup>1</sup> University of Padova, Padova, Italy

<sup>2</sup> University of Padova, Padova, Italy

This is a rigorously conducted and well-written study describing the “genetic architecture” of dystrophinopathy in 43 patients from two neuromuscular Centers in an Indonesian city. The literature is quite rich of such papers, showing mutational composition of dystrophinopathy

cohorts from different world populations, and these are indeed, as the authors claim, useful for directing local health interventions and policies. However, it would be in my opinion also useful to point out that, in sufficiently large populations, the overall genetic composition of dystrophinopathies tends to be very similar across world populations, as there are no or very few “founder” mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations.

Moreover, I have some comments and suggestions, as listed below:

1. Table 3: Out-of-frame duplications are not amenable to exon skipping.
2. Also skipping of exon 55 for del 56-74 is very theoretical (no dystroglycan binding in the expected protein product).
3. c.6808delT is not a nonsense mutation, but rather a frameshift deletion of 1 nucleotide; therefore a DMD phenotype is expected. The fact that the patient walks at age 9 (with corticosteroid treatment?) does not exclude a DMD phenotype. This patient should **not** be treated with ataluren.
4. How many of the 43 cases are related cases (siblings, cousins, other)? This point is also relevant for the discussion of de novo frequency in the population (the more siblings, the less de novo).
5. The 12-nucleotide deletion in exon 65 may disrupt binding to  $\beta$ -dystroglycan, a potential explanation for a severe phenotype despite ORF preservation in this patient.
6. Figure 5 (pedigrees) is not very useful, as X-linked inheritance is expected and always confirmed.
7. “Gowers” instead of “Gower”.
8. Are the Centers where the data were collected exclusively pediatric? This may exclude from this population the spectrum of milder BMD which only becomes clinically evident in adult age, and should be considered in the discussion (i.e. underestimation of in-frame mutations).
9. For reference 3 I would suggest Monaco *et al.* (1988<sup>1</sup>), rather than, or in addition to, the current reference.

## References

1. Monaco A, Bertelson C, Liechti-Gallati S, Moser H, et al.: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. 1988; **2** (1): 90-95 [Publisher Full Text](#)

## Is the work clearly and accurately presented and does it cite the current literature?

Yes

## Is the study design appropriate and is the work technically sound?



Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Muscular dystrophy

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 03 Nov 2023

**Poh San Lai**

**Response to reviewer:**

*1. Table 3: Out-of-frame duplications are not amenable to exon skipping.*

Response: Thank you for the comment. We have amended Table 3 to remove this.

*2. Also skipping of exon 55 for del 56-74 is very theoretical (no dystroglycan binding in the expected protein product).*

Response: Thank you for the comment. We have amended Table 3 to remove this.

*3. c.6808delT is not a nonsense mutation, but rather a frameshift deletion of 1 nucleotide; therefore a DMD phenotype is expected. The fact that the patient walks at age 9 (with corticosteroid treatment?) does not exclude a DMD phenotype. This patient should **not** be treated with ataluren.*

Response: Thank you for pointing out the error. We agree that ataluren will not affect the patient with the frameshift deletion and have revised Table 3.

4. *How many of the 43 cases are related cases (siblings, cousins, other)? This point is also relevant for the discussion of de novo frequency in the population (the more siblings, the less de novo).*

Response: Thank you for the comment. We checked again and none of related cases was included in this study.

5. *The 12-nucleotide deletion in exon 65 may disrupt binding to  $\beta$ -dystroglycan, a potential explanation for a severe phenotype despite ORF preservation in this patient.*

Response: Thank you very much for your insight. We have added this to the 4<sup>th</sup> paragraph of the discussion section. All changes are highlighted in yellow in the manuscript text.

6. *Figure 5 (pedigrees) is not very useful, as X-linked inheritance is expected and always confirmed.*

Response: Thank you for the suggestion, we have removed Figure 5 from the revised manuscript.

7. *"Gowers" instead of "Gower".*

Response: Thank you for pointing this out. We have made the revision.

8. *Are the Centers where the data were collected exclusively pediatric? This may exclude from this population the spectrum of milder BMD which only becomes clinically evident in adult age and should be considered in the discussion (i.e. underestimation of in-frame mutations).*

Response: Thank you very much for this important point. We agree and have added this point in the penultimate paragraph of the discussion section.

9. *For reference 3 I would suggest Monaco et al. (1988<sup>1</sup>), rather than, or in addition to, the current reference.*

Response: Thank you for the suggestion. We have revised reference 3.

10. *"However, it would be in my opinion also useful to point out that, in sufficiently large populations, the overall genetic composition of dystrophinopathies tends to be very similar across world populations, as there are no or very few "founder" mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations".*

Response: We have added this suggested comment in the discussion section as “Nonetheless, it should be noted that when sufficiently large populations of patients are analyzed, the overall genetic composition of dystrophinopathies tends to be very similar across world populations, as there are no or very few “founder” mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations”.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 25 April 2023

<https://doi.org/10.5256/f1000research.143201.r162602>

© 2023 Sasongko T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Teguh Haryo Sasongko** 

<sup>1</sup> Graduate School of Medicine, Perdana University-RCSI, Serdang, Malaysia

<sup>2</sup> Center for Research Excellence, Perdana University-RCSI, Serdang, Malaysia

<sup>3</sup> Graduate School of Medicine, Perdana University-RCSI, Serdang, Malaysia

<sup>4</sup> Center for Research Excellence, Perdana University-RCSI, Serdang, Malaysia

The authors have sufficiently addressed all concerns. No further comment.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Human Molecular Genetics and Rare Diseases

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

Version 1

Reviewer Report 22 March 2022

<https://doi.org/10.5256/f1000research.77130.r122827>

© 2022 Sasongko T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Teguh Haryo Sasongko** 

- <sup>1</sup> Graduate School of Medicine, Perdana University-RCSI, Serdang, Malaysia
- <sup>2</sup> Center for Research Excellence, Perdana University-RCSI, Serdang, Malaysia
- <sup>3</sup> Graduate School of Medicine, Perdana University-RCSI, Serdang, Malaysia
- <sup>4</sup> Center for Research Excellence, Perdana University-RCSI, Serdang, Malaysia

The authors described their findings on the mutations of DMD gene in Indonesian patients with Duchenne/Becker Muscular Dystrophy. This the first report from Indonesia on the use of MLPA for the molecular diagnosis of DMD, well-written, and with balance clinical, pathological and molecular data.

There are a few concerns raised:

1. I believe clinical diagnosis was the basis for patients' inclusion into the study. There are 8 patients without evident deletion or duplication. There should be enough information how these patients were clinically categorized into DMD or BMD or they were simply MD pending molecular confirmation (eg. (a) if the clinical diagnosis/examination was made by qualified neurologist/pediatrician (b) information on dmd22 and dmd26 may be very limited to warrant specific clinical diagnosis of DMD. There was no evident loss of dystrophin in these patients).
2. Page 4 mentioned that databases were accessed on 6 June 2021. It will be worthwhile to have an updated comparison as almost a year has lapsed.
3. Table 1 on the column "Age when wheelchair bound", it will be clearer to replace "not yet" with "still ambulant".
4. Table 2 is redundant as the content would have been explained by Table 1.
5. Table 3 and 4 may be combined to focus on discrepancy findings (genotype vs phenotype; IHC vs phenotype).

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

No

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

No

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Human Molecular Genetics and Rare Diseases

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 13 Jan 2023

**Poh San Lai**

1. I believe clinical diagnosis was the basis for patients' inclusion into the study. There are 8 patients without evident deletion or duplication. There should be enough information how these patients were clinically categorized into DMD or BMD or they were simply MD pending molecular confirmation (eg. (a) if the clinical diagnosis/examination was made by qualified neurologist/pediatrician (b) information on dmd22 and dmd26 may be very limited to warrant specific clinical diagnosis of DMD. There was no evident loss of dystrophin in these patients).

Response :

a. The diagnosis was made by qualified pediatric neurologists in our hospital, with enough years of experiences and also hold degree of PhD in area of genetic and muscular dystrophy. We have added explanation about this in the method section.

b. DMD/BMD are the most common muscular dystrophy with the patients showing gower signs, difficulty in walking, increase CK level, AST or ALT at clinical level. This clinical screening was recommended by previous study as well (1, 2). Male-young patients with

those clinical condition may have high possibility of having *DMD* gene mutation and enough reason to do screening with either immunohistochemistry (from tissue biopsy) or MLPA (form blood).

Unfortunately for patient DMD22 and DMD26, the muscle biopsy was not performed due to consent problem as it is an invasive procedure. Even though immunohistochemistry result was not available, and genetic analysis of MLPA did not reveal any mutation, we believe the clinical data is enough to include the patients. Further tests need to be done to identify possible small mutations using DNA sequencing. We explained about this in the 7<sup>th</sup> paragraph of discussion section (highlighted).

2. Page 4 mentioned that databases were accessed on 6 June 2021. It will be worthwhile to have an updated comparison as almost a year has lapsed.

Response: This is an important suggestion. However due to technical difficulties, especially during the pandemic situation, we have been unable to perform a comprehensive database update. Therefore our most current data is from 6 June 2021.

3. Table 1 on the column "Age when wheelchair bound", it will be clearer to replace "not yet" with "still ambulant".

Response : Thank you very much for this suggestion. The suggestion has been incorporated in our manuscript.

4. Table 2 is redundant as the content would have been explained by Table 1.

Response : Thank you very much for this suggestion, this table has been removed. Table numbers have been updated accordingly throughout the manuscript.

Table 3 and 4 may be combined to focus on discrepancy findings (genotype vs phenotype; IHC vs phenotype).

Response: Thank you very much for this suggestion, table 3 and 4 have been combined. Table numbers have been updated accordingly throughout the manuscript.

**Competing Interests:** No competing interests were disclosed.

---

Author Response 28 Oct 2023

**Poh San Lai**

Response to reviewer

1. Table 3: Out-of-frame duplications are not amenable to exon skipping.

Response: Thank you for the comment. We have amended Table 3 to remove this.

2. Also skipping of exon 55 for del 56-74 is very theoretical (no dystroglycan binding in the

expected protein product).

Response: Thank you for the comment. We have amended Table 3 to remove this.

3. c.6808delT is not a nonsense mutation, but rather a frameshift deletion of 1 nucleotide; therefore a DMD phenotype is expected. The fact that the patient walks at age 9 (with corticosteroid treatment?) does not exclude a DMD phenotype. This patient should not be treated with ataluren.

Response: Thank you for pointing out the error. We agree that ataluren will not affect the patient with the frameshift deletion and have revised Table 3.

4. How many of the 43 cases are related cases (siblings, cousins, other)? This point is also relevant for the discussion of de novo frequency in the population (the more siblings, the less de novo).

Response: Thank you for the comment. We checked again and none of related cases was included in this study.

5. The 12-nucleotide deletion in exon 65 may disrupt binding to  $\beta$ -dystroglycan, a potential explanation for a severe phenotype despite ORF preservation in this patient.

Response: Thank you very much for your insight. We have added this to the 4th paragraph of the discussion section. All changes are highlighted in yellow in the manuscript text.

6. Figure 5 (pedigrees) is not very useful, as X-linked inheritance is expected and always confirmed.

Response: Thank you for the suggestion, we have removed Figure 5 from the revised manuscript.

7. "Gowers" instead of "Gower".

Response: Thank you for pointing this out. We have made the revision.

8. Are the Centers where the data were collected exclusively pediatric? This may exclude from this population the spectrum of milder BMD which only becomes clinically evident in adult age and should be considered in the discussion (i.e. underestimation of in-frame mutations).

Response: Thank you very much for this important point. We agree and have added this point in the penultimate paragraph of the discussion section.

9. For reference 3 I would suggest Monaco et al. (19881), rather than, or in addition to, the current reference.

Response: Thank you for the suggestion. We have revised reference 3.

10. "However, it would be in my opinion also useful to point out that, in sufficiently large populations, the overall genetic composition of dystrophinopathies tends to be very similar across world populations, as there are no or very few "founder" mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations".

Response: We have added this suggested comment in the discussion section as "Nonetheless, it should be noted that when sufficiently large populations of patients are

analyzed, the overall genetic composition of dystrophinopathies tends to be very similar across world populations, as there are no or very few “founder” mutations (because of the severe phenotype and X-linked nature) and most, if not all identified mutations, usually date back to just a few generations”.

**Competing Interests:** No competing interests were disclosed.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**